全文获取类型
收费全文 | 166297篇 |
免费 | 33047篇 |
国内免费 | 2520篇 |
专业分类
耳鼻咽喉 | 5288篇 |
儿科学 | 5698篇 |
妇产科学 | 2639篇 |
基础医学 | 5219篇 |
口腔科学 | 2018篇 |
临床医学 | 28339篇 |
内科学 | 50785篇 |
皮肤病学 | 7790篇 |
神经病学 | 16840篇 |
特种医学 | 7517篇 |
外科学 | 43428篇 |
综合类 | 322篇 |
现状与发展 | 72篇 |
一般理论 | 7篇 |
预防医学 | 7507篇 |
眼科学 | 3709篇 |
药学 | 1813篇 |
中国医学 | 19篇 |
肿瘤学 | 12854篇 |
出版年
2024年 | 694篇 |
2023年 | 4910篇 |
2022年 | 1474篇 |
2021年 | 3545篇 |
2020年 | 6307篇 |
2019年 | 2516篇 |
2018年 | 7805篇 |
2017年 | 7697篇 |
2016年 | 8892篇 |
2015年 | 8928篇 |
2014年 | 16148篇 |
2013年 | 16384篇 |
2012年 | 6737篇 |
2011年 | 6737篇 |
2010年 | 11171篇 |
2009年 | 14983篇 |
2008年 | 6922篇 |
2007年 | 5276篇 |
2006年 | 7512篇 |
2005年 | 4844篇 |
2004年 | 4039篇 |
2003年 | 2942篇 |
2002年 | 2929篇 |
2001年 | 3937篇 |
2000年 | 3118篇 |
1999年 | 3349篇 |
1998年 | 3790篇 |
1997年 | 3573篇 |
1996年 | 3447篇 |
1995年 | 3269篇 |
1994年 | 2002篇 |
1993年 | 1625篇 |
1992年 | 1414篇 |
1991年 | 1437篇 |
1990年 | 1071篇 |
1989年 | 1203篇 |
1988年 | 1044篇 |
1987年 | 865篇 |
1986年 | 900篇 |
1985年 | 727篇 |
1984年 | 559篇 |
1983年 | 535篇 |
1982年 | 524篇 |
1981年 | 406篇 |
1980年 | 369篇 |
1979年 | 316篇 |
1978年 | 344篇 |
1977年 | 409篇 |
1975年 | 283篇 |
1972年 | 309篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
12.
13.
14.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
15.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
16.
17.
18.
19.
Peter Düking Christoph Zinner Jennifer L. Reed Hans-Christer Holmberg Billy Sperlich 《Scandinavian journal of medicine & science in sports》2020,30(12):2291-2304
Monitoring variations in the functioning of the autonomic nervous system may help personalize training of runners and provide more pronounced physiological adaptations and performance improvements. We systematically reviewed the scientific literature comparing physiological adaptations and/or improvements in performance following training based on responses of the autonomic nervous system (ie, changes in heart rate variability) and predefined training. PubMed, SPORTDiscus, and Web of Science were searched systematically in July 2019. Keywords related to endurance, running, autonomic nervous system, and training. Studies were included if they (a) involved interventions consisting predominantly of running training; (b) lasted at least 3 weeks; (c) reported pre- and post-intervention assessment of running performance and/or physiological parameters; (d) included an experimental group performing training adjusted continuously on the basis of alterations in HRV and a control group; and (e) involved healthy runners. Five studies involving six interventions and 166 participants fulfilled our inclusion criteria. Four HRV-based interventions reduced the amount of moderate- and/or high-intensity training significantly. In five interventions, improvements in performance parameters (3000 m, 5000 m, Loadmax, Tlim) were more pronounced following HRV-based training. Peak oxygen uptake () and submaximal running parameters (eg, LT1, LT2) improved following both HRV-based and predefined training, with no clear difference in the extent of improvement in . Submaximal running parameters tended to improve more following HRV-based training. Research findings to date have been limited and inconsistent. Both HRV-based and predefined training improve running performance and certain submaximal physiological adaptations, with effects of the former training tending to be greater. 相似文献